Yesterday (October 24th), leading medical aesthetics company IMEiK Technology Development Co., Ltd. (referred to as “IMEiK”) released its third-quarter financial report.
In the first nine months of 2023, IMEiK’s operating income reached 2.17 billion yuan ($296.8 million), a year-on-year growth of 45.71%. The net profit attributable to shareholders was 1.418 billion yuan ($193.9 million), a year-on-year increase of 43.74%. The basic earnings per share were 6.56 yuan ($0.9), a year-on-year growth of 43.86%. The net profit for the third quarter was 455 million yuan ($62.22 million), with a adjusted year-on-year growth of 13.27%.
In addition to the release of the third-quarter financial report, IMEiK also issued an announcement regarding the delay of some raised capital investment projects.
The announcement stated that the company is actively advancing its genetic recombinant protein drug development project, enriching its product research and development pipeline. Currently, the research and development project is in the “pre-clinical research” stage. Regarding the raised capital investment project, the “Genetic Recombinant Protein Production Base Construction Project,” the site selection, production methods, and production start time are still under discussion. Therefore, as of now, the construction of the genetic recombinant protein research and production base has not yet started.
Considering the actual situation of the project, IMEiK intends to apply for a delay adjustment for the above-mentioned raised investment project. The expected timeframe for the project’s utilization is proposed to be changed from the end of this year to December 2025.
